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Viruses such as lentiviruses that are responsible for long lasting infections have to evade
several levels of cellular immune mechanisms to persist and efﬁciently disseminate in
the host. Over the past decades, much evidence has emerged regarding the major role
of accessory proteins of primate lentiviruses, human immunodeﬁciency virus and simian
immunodeﬁciency virus, in viral evasion from the host immune defense. This short review
will provide an overview of the mechanism whereby the accessory proteinVpu contributes
to this escape. Vpu is a multifunctional protein that was shown to contribute to viral egress
by down-regulating several mediators of the immune system such as CD4, CD1d, NTB-
A and the restriction factor BST2. The mechanisms underlying its activity are not fully
characterized but rely on its ability to interfere with the host machinery regulating protein
turnover and vesicular trafﬁcking. This review will focus on our current understanding of
the mechanisms whereby Vpu down-regulates CD4 and BST2 expression levels to favor
viral egress.
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INTRODUCTION
Viral egress and replication rely on a complex interplay between
viral and cellular proteins. During their replication cycle, viruses,
notably lentiviruses, have to face several levels of the host immune
defense mechanisms and must counteract these barriers to per-
sist and disseminate in the host. Understanding the mechanisms
underlying lentiviruses evasion from host antiviral activities has
been the focus of many studies of the past decades. Not only did
they contribute to major advances in the characterization of host
strategies to repress viral replication, notably by the identiﬁca-
tion of antiviral cellular proteins such as APOBEC3G, SAMHD1,
TRIM5α, and BST2 referred to as restriction factors (Sheehy et al.,
2002; Stremlau et al., 2004; Neil et al., 2008; Van Damme et al.,
2008; Laguette et al., 2011), but also they unraveled the impor-
tance of the accessory proteins of viruses in this process (Malim
and Bieniasz, 2012).
The genome of lentiviruses encodes for several accessory pro-
teins such as Nef, Vif, Vpr, Vpx, and Vpu, in addition to the struc-
tural and enzymatic proteins Gag, Pol, and Env and the regulatory
proteins Tat and Rev (Malim and Bieniasz, 2012). These accessory
proteins are, however, not common to all lentiviruses: Nef andVpr
are speciﬁc of primate lentiviruses (HIV-1,HIV-2, and SIV),Vpx is
expressed byHIV-2 and its closely related SIVsmm and SIVmac,Vpu
is expressed by HIV-1 strains and a few strains of SIV (described
later; Malim and Emerman, 2008). These proteins are not strictly
required for viral replication in vitro. However,much evidence has
highlighted their importance in the pathogenesis of the infection,
as they contribute to modify the cell environment to facilitate viral
replication and evasion from the host antiviral immune response
(Malim and Emerman, 2008).
This review will provide an overview of our current under-
standing of the mechanisms whereby the accessory protein Vpu
exploits the host cell machineries to counteract two components
of the adaptive and innate host immune system: the protein CD4
and the restriction factor BST2.
CHARACTERISTICS AND FUNCTIONS OF THE ACCESSORY
PROTEIN VPU
The accessory protein Vpu is an 81-amino acid type I integral
membrane phosphoprotein, expressed by the genome of HIV-1,
the related SIVcpz (Strebel et al., 1988) and the SIVgsn lineages
including the greater spot-nosed monkey (SIVgsn), the mona
monkey (SIVmon), the mustached monkey (SIVmus) and Dent’s
mona monkey (SIVden) isolates (Gao et al., 1999; Courgnaud
et al., 2002, 2003; Bailes et al., 2003). Vpu contains a short lumi-
nal N-terminal domain, a 23-amino acid transmembrane domain
and a large cytoplasmic C-terminal domain (Strebel et al., 1988;
Maldarelli et al., 1993). Vpu localizes mainly in the endoplasmic
reticulum (ER), the trans–Golgi network (TGN) and endoso-
mal compartments. Two major functions have been attributed
to Vpu during HIV-1 replication cycle. Firstly, Vpu targets the
newly synthesized CD4 receptor for proteasomal degradation
(Willey et al., 1992a). Secondly, it favors the release of viral par-
ticles from most human cell types through counteracting the
inhibitory effect of BST2 (Neil et al., 2008; Van Damme et al.,
2008). More recently, Vpu was shown to down-regulate cell
surface expression of two additional mediators of the immune
response: the lipid-antigen presenting protein CD1d expressed
by antigen-presenting cells (Moll et al., 2010) and the natural
killer cells ligand NTB-A (Shah et al., 2010). Vpu appears there-
fore as a key factor for HIV evasion from the host immune
system.
VPU-INDUCED DOWN-REGULATION OF CD4
CD4 constitutes the major component of the receptor complex
used by primate lentiviruses to infect the cells. It is a 54 kDa
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type I integral glycoprotein expressed at the surface of helper
T-lymphocytes, cells of the monocyte/macrophage lineage and
hematopoietic progenitor cells.
Infection of CD4+ cells by primate lentiviruses results in a
rapid and constant down-modulation of cell surface CD4 expres-
sion level (Ray and Doms, 2006). CD4 down-regulation was
proposed to prevent lethal superinfection of cells by additional
virions (Wildum et al., 2006), contribute to the escape of infected
cells from the immune system and favor viral ﬁtness (Willey
et al., 1992b). CD4 depletion in infected cells is achieved by the
concerted, though mechanistically distinct, action of three viral
proteins: Nef, Vpu and, to a lower extent, Env (Wildum et al.,
2006). Nef, produced shortly after infection, enhances internal-
ization of pre-existing CD4 from the cell surface and targets the
receptor for lysosomal degradation (Chaudhuri et al., 2007). Env
precursor gp160 binds CD4 in the ER and blocks its transport
to the cell surface (Crise et al., 1990; Jabbar and Nayak, 1990).
Vpu targets CD4 molecules present in the ER for proteasomal
degradation (Willey et al., 1992a).
Vpu induces degradation of newly synthesized CD4 by a multi-
step process involving binding of Vpu with CD4 via their trans-
membrane domains (TMD), retention and poly-ubiquitination
of CD4 in the ER, followed by its delivery to the ER-associated
degradation pathway (ERAD) for further proteasomal degra-
dation (Magadan et al., 2010; Magadan and Bonifacino, 2012;
Figure 1). Vpu-induced degradation of CD4 requires the integrity
of two phosphoserines S52/S56 present in a canonical DSGXXS
motif within the cytoplasmic tail of Vpu and involved in an
interaction with the β-transducin repeat-containing protein 1
or 2 (β-TrCP1; β-TrCP2), two adaptors for the SKP1-cullin1-F-
Box (SCF) E3 ubiquitin ligase complex (Margottin et al., 1998).
Recruitment of the SCFß-TrCP complex by Vpu results in poly-
ubiquitination of the cytoplasmic tail of CD4 on lysine, serine
and threonine residues (Magadan et al., 2010). Interestingly, Vpu-
induced SCF-mediated poly-ubiquitination of CD4 contributes
to retain the receptor in the ER and enables the recruitment
of the ERAD VCP-UFD1L-NPL4 dislocase complex, leading to
the extraction of CD4 from the ER membrane and its sub-
sequent degradation by the proteasome (Magadan et al., 2010;
Figure 1).
VPU-MEDIATED ANTAGONISM OF THE RESTRICTION
FACTOR BST2
A major breakthrough in understanding how Vpu promotes the
release of HIV-1 particles was made by the identiﬁcation of BST2
as a restriction factor for HIV-1 release (Neil et al., 2008; Van
Damme et al., 2008).
CHARACTERISTICS OF BST2
BST2 is a 30–36 kDa highly glycosylated type II integralmembrane
protein, constitutively expressed in several cell types and can be
up-regulated by type-I interferon and pro-inﬂammatory stimuli
(Neil, 2013). BST2 is composed of a short N-terminal cytoplas-
mic tail, linked to a transmembrane domain and an extracellular
domain anchored to themembrane through aC-terminal glycosyl-
phosphatidylinositol (GPI) moiety (Kupzig et al., 2003). Recently,
a short isoform of BST2 produced by an alternative translation
initiation from the methionine residue at position 13 has been
identiﬁed (Cocka and Bates, 2012). BST2 is localized at the plasma
membrane (PM) in cholesterol–rich microdomains (rafts) and in
intracellular compartments such as the TGN as well as early and
recycling endosomes (Kupzig et al., 2003; Masuyama et al., 2009).
BST2 was proposed to assemble as a “picket fence” around the
lipid rafts, playing a role in organizing membrane microdomains
(Billcliff et al., 2013). BST2 was shown to physically trap the
de novo formed mature viral particles at the surface of infected
cells, thereby considerably reducing virus release (Neil et al., 2008;
Van Damme et al., 2008; Perez-Caballero et al., 2009; Hammonds
et al., 2010). This activity relies on BST2 ability to form parallel
disulﬁde–bond homo-dimers and to bridge virions and cellu-
lar membranes via its N– and C–terminal membrane anchoring
domains (Iwabu et al., 2009; Perez-Caballero et al., 2009; Schu-
bert et al., 2010), with a preference for an “axial” conﬁguration in
which theGPI anchors are inserted into virions, and theN-termini
transmembrane anchors remain in the infected cells membrane
(Venkatesh and Bieniasz, 2013).
Although initially identiﬁed as the factor responsible for defec-
tive release of HIV-1 mutants lacking the accessory gene vpu
(Neil et al., 2008; Van Damme et al., 2008), it is now well estab-
lished that BST2 restricts the release of nearly all enveloped
viruses (retroviruses, herpes viruses, ﬁloviruses, rhabdoviruses,
paramyxoviruses, and arenaviruses) (Neil, 2013). BST2 therefore
appears as a major mediator of the innate immune defense against
viral dissemination. Primates lentiviruses deploy three proteins to
antagonize BST2 antiviral activity: Vpu in HIV-1 (Neil et al., 2008;
Van Damme et al., 2008); Env in HIV-2 ROD10, HIV-2 RODA,
SIVagmTan and SIVmac239nef isolates (Gupta et al., 2009b; Le
Tortorec and Neil, 2009; Hauser et al., 2010; Serra-Moreno et al.,
2011) and Nef in most isolates of SIV (Jia et al., 2009; Sauter et al.,
2009; Zhang et al., 2009). HIV-1 Vpu, HIV-2 Env, and SIV Nef
were shown to down-regulate the cell surface expression level of
BST2 to favor its removal from viral budding sites and further viral
release (Neil, 2013). To date, the precise mechanism involved in
this process has not been fully characterized.
BINDING OF VPU WITH BST2
Binding of Vpu with BST2 through their respective TMD was
shown to be essential to counteract BST2 antiviral activity. Muta-
genesis analyzes have unraveled the critical role of residues I34,
L37, L41 of BST2 and A14, W22 and to some extent A18 of Vpu
in this interaction (Vigan and Neil, 2010; Kobayashi et al., 2011).
These residues were proposed to form an anti-parallel helix-helix
interface (Skasko et al., 2012). Interestingly, recent studies have
identiﬁed additional residues, located at the periphery of the
TMD of BST2 and Vpu respectively, required for the interaction
between both proteins and antagonism of BST2 (McNatt et al.,
2013; Pickering et al., 2014).
VPU-INDUCED CELL SURFACE DOWN-REGULATION OF BST2
The mechanism whereby Vpu decreases cell surface BST2 expres-
sion appears to rely on interference with BST2 intracellular
trafﬁcking. BST2 was thought to cycle between the PM, the
TGN and the endosomes, with a fraction sorted for lysosomal
degradation through an Endosomal Sorting Complexes Required
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FIGURE 1 | Vpu mediates proteasomal degradation of CD4 to favor
viral fitness. (A) Newly synthetized CD4 and HIV-1 envelope precursor
gp160 interact in the ER through their luminal domain, preventing Env
trafﬁcking to the cell surface. (B) Vpu induces retention of CD4 in the
ER through interaction via their transmembrane region and connects
CD4 to SKP1-cullin1-F-Box (SCF) E3 ubiquitin ligase through binding with
the SCF subunits β-TrCP1 and β-TrCP2. Interaction of Vpu with β-TrCP
involves the conserved phophorylated serines S52 and S56, located in
the cytoplasmic tail of Vpu. Recruitment of the SCFß-TrCP complex by
Vpu induces poly-ubiquitination of CD4 on lysine, serine and threonine
residues in its cytoplasmic tail. Poly-ubiquitination of CD4 partially
contributes its retention in the ER, through a yet-to-be-determined
mechanism. Vpu-induced SCF-mediated poly-ubiquitination of CD4
enables the recruitment of the ERAD VCP-UFD1L-NPL4 dislocase
complex, leading to the extraction of CD4 from the ER membrane
and its subsequent degradation by the proteasome. Degradation of
CD4 by Vpu was proposed to dissociate CD4 from newly synthesized
viral Env present in the ER, allowing Env maturation and trafﬁcking
to the cell surface for its subsequent incorporation in the forming
virions.
for Transport (ESCRT)-mediated pathway (Rollason et al., 2007;
Masuyama et al., 2009; Habermann et al., 2010; Janvier et al.,
2011). Internalization of BST2 from the PM occurs through
clathrin-coated vesicles, via direct binding of the clathrin adaptor
complexesAP2withnon-canonical dual tyrosine residues (Y6XY8)
in the cytoplasmic tail of BST2 (Rollason et al., 2007; Masuyama
et al., 2009). Binding of BST2 with AP1 complexes regulates its
retrieval from the early endosomes back to the TGN (Rollason
et al., 2007). Vpu does not increase the rate of BST2 endocytosis
but rather slows down the recycling of internalized BST2 back to
the PM and inhibits the access of de novo synthetized BST2 to the
cell surface, thereby decreasing the resupply of BST2 to the PM
(Mitchell et al., 2009; Dube et al., 2011; Lau et al., 2011; Schmidt
et al., 2011; Figure 2).
In some cell types such as T-cells and primary macrophages,
antagonism of BST2 by Vpu is not associated with decreased
expression of cell surface BST2 (Miyagi et al., 2009; Chu et al.,
2012), consistent with the view that Vpu promotes viral release
by displacing BST2 from viral budding sites at the PM. Using
a sophisticated approach, it has been recently suggested that
this function relies on the integrity of a “dileucine”-like motif
E59VSAL63V in the cytoplasmic tail of Vpu (McNatt et al., 2013),
ﬁrst reported to be essential for Vpu to down-regulate CD4 and
BST2 expression and counteract BST2 antiviral activity (Hill et al.,
2010; Kueck and Neil, 2012). How this motif contributes to these
functions is, however unclear. Vpu EXXXLV motif ﬁts the con-
sensus dileucine – based sorting signal (D/E)XXXL(L/I/M) that
mediates binding to the AP complexes. However, evidence for an
interaction of Vpu with the AP complexes or a direct contribution
of these complexes in Vpu’s functions could not be demonstrated
(Kueck and Neil, 2012).
VPU-MEDIATED DEGRADATION OF BST2
In some cell types, Vpu-induced down-regulation of cell surface
BST2 is associated with enhanced targeting of the cellular pro-
tein to the degradation pathway (Gupta et al., 2009a; Mitchell
et al., 2009). This process is ubiquitin-dependent and requires the
recruitment of the SCFß-TrCP complex by Vpu via its DS52GxxS56
motif (Douglas et al., 2009; Gofﬁnet et al., 2009; Mangeat et al.,
2009; Mitchell et al., 2009; Tokarev et al., 2010). The importance
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FIGURE 2 | Vpu subverts the host cell trafficking and ubiquitin
machineries to counteract BST2 antiviral activity. BST2 physically tethers
HIV-1 particles on the surface of infected cells preventing their release and
further dissemination. The accessory protein Vpu counteracts this restriction
by hijacking the host machineries involved in BST2 trafﬁcking and turnover.
BST2 cycles between the plasma membrane, theTGN and the endosomes,
with a fraction sorted for lysosomal degradation through an ESCRT-mediated
pathway (left panel). Vpu counteracts BST2 restriction activity through
(i) displacing it from viral assembly sites by a yet-to-be-determined
mechanism involving a “dileucine”-like motif located in its cytoplasmic tail
and (ii) down-regulating BST2 cell surface expression level and as such
restores viral release. Vpu down-regulates cell surface BST2 by slowing down
the PM access of internalized and newly synthesized BST2. Vpu-induced
BST2 cell surface down regulation is associated with targeting of the
restriction factor for lysosomal degradation through an ubiquitin-dependent
mechanism that involves the recruitment of SCFß-TrCP E3 ubiquitin ligase
complex and the ESCRT machinery. Indeed, through binding to HRS, Vpu
enhances the afﬁnity of BST2 for HRS thus accelerating its sorting by the
ESCRT machinery for lysosomal degradation. One might propose that
through binding with the ESCRT machinery, Vpu may favor the sorting of
BST2 at the level of endosomes, thereby reducing its recycling to the plasma
membrane (right panel). This ﬁgure is adapted from Janvier et al. (2012).
of β-TrCP in Vpu-mediated antagonism of BST2 antiviral activity
remains controversial to date (Douglas et al., 2009; Iwabu et al.,
2009; Mangeat et al., 2009; Mitchell et al., 2009; Miyagi et al.,
2009; Tervo et al., 2011). BST2 undergoes ubiquitination on lysine
residues located in its cytoplasmic tail (Pardieu et al., 2010). Inter-
estingly, Vpu increases BST2 ubiquitination on lysine/serine and
threonine residues located in its cytoplasmic tail, as is also observed
withCD4 (Tokarev et al., 2010). Mutationof these residues reduces
Vpu-induced antagonism of BST2. Consistent with this obser-
vation, the short isoform of BST2 lacking these residues shows
decreased sensitivity to Vpu antagonism (Tokarev et al., 2010;
Cocka and Bates, 2012). One study challenged the requirement
of the S3T4S5 residues in Vpu-induced ubiquitination of BST2
(Gustin et al., 2012) but no explanation has been proposed for this
discrepancy.
Despite the similarity in the molecular mechanisms underlying
Vpu-induced ubiquitination and degradation of CD4 and BST2,
the fate of both proteins differs. Indeed, it is now well established
that Vpu does not target BST2 for proteasomal degradation but
induces β-TrCP-dependent lysosomal sorting of BST2 (Douglas
et al., 2009; Iwabu et al., 2009; Mitchell et al., 2009). In agree-
ment with this notion, we highlighted a major role of Rab7, a
regulator of the endo/lysosomal trafﬁcking, in this process (Cail-
let et al., 2011), and revealed that Vpu enhances ESCRT-mediated
sorting of BST2 for degradation (Janvier et al., 2011). The ESCRT
machinery is a set of four hetero-oligomeric protein complexes
involved in the sorting of ubiquitinated membrane proteins into
vesicles budding into endosomes for their subsequent degrada-
tion in the lysosomes. The ESCRT-0 protein HRS (hepatocyte
growth factor-regulated tyrosine kinase substrate) coordinates this
process by linking ubiquitinated cargoes and the ESCRT-I com-
ponent TSG101 (Raiborg and Stenmark, 2009). We showed that
Vpu-mediated down-regulation of BST2 and viral release require
HRS,andunveiled an increased afﬁnity of BST2 forHRSuponVpu
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expression (Janvier et al., 2011). One might propose that through
binding with HRS and BST2, Vpu accelerates ESCRT-mediated
sorting of BST2 to the lysosomes, thereby reducing its recycling
to the PM (Janvier et al., 2012; Figure 2). Further evidence of
the requirement of the ESCRT machinery in Vpu-mediated BST2
degradationwas obtained by the characterization of a new compo-
nent of the ESCRT-I machinery: the protein UBAP1 (Agromayor
et al., 2012). Depletion of UBAP1 abolishes Vpu-induced degra-
dation of BST2, but has no impact on Vpu antagonism of BST2
antiviral activity (Agromayor et al., 2012), consistent with the
notion that degradation of BST2 is not strictly required for Vpu-
mediated antagonism of BST2 (Miyagi et al., 2009; Gofﬁnet et al.,
2010).
VPU AND BST2 VIRAL SENSING ACTIVITY
In addition to its activity as a restriction factor of viral release,
BST2 has been recently characterized as an innate immune sen-
sor for HIV (Cocka and Bates, 2012; Galao et al., 2012; Tokarev
et al., 2013). In 2003, BST2 was ﬁrst reported to stimulate the
activity of the NF-κB family of transcription factors, using a
whole-genome cDNA screen (Matsuda et al., 2003). Recent stud-
ies further revealed that tethered HIV particles increase BST2
signaling activity, resulting in enhanced production of pro-
inﬂammatory stimuli, consistent with a role of BST2 as a sensor
for assembled viruses (Cocka and Bates, 2012; Galao et al., 2012;
Tokarev et al., 2013). This function seems separable from its activ-
ity as an inhibitor of viral release and relies on the integrity
of the non-canonical dual tyrosine residues (Y6XY8) regulating
its trafﬁcking (Galao et al., 2012; Tokarev et al., 2013). Whether
BST2 trafﬁcking is relevant for its signaling activity is unclear.
BST2 was proposed to activate the “canonical” NF-κB pathway
through engaging mediators of this pathway via its tyrosine motif
(Galao et al., 2012; Tokarev et al., 2013). Regulation of this pathway
depends on the activation of the transforming growth factor-β-
activated kinase-1 (TAK1)/TAK1-binding protein 1 and 2 (TAB1
and TAB2) complex, through poly-ubiquitination by E3 ligases of
the TNF receptor-associated factors (TRAFs) family (Skaug et al.,
2009). Interestingly, BST2 was shown to co-immunoprecipitate
with TRAF2, TRAF6 as well as the TAK1/TAB1 complex (Galao
et al., 2012; Tokarev et al., 2013).
Vpu was shown to counteract BST2 signaling activity through
a β-TrCP-dependent mechanism (Tokarev et al., 2013). Interest-
ingly, over a decade ago,Vpu was shown to sequester β-TrCP away
from its substrates and inhibitNF-κBactivationby interferingwith
β-TrCP-mediated degradation of the NF-κB inhibitor IκB (Bour
et al., 2001; Besnard-Guerin et al., 2004). Whether this mecha-
nismaccounts solely forVpu-induced inhibition of BST2 signaling
activity requires further investigation. Furthermore, many ques-
tions remain regarding how viral expression triggers BST2 sensing
activity.
CONCLUDING REMARKS
Over the past decade, Vpu has emerged as an important asset
for viral egress and evasion from the host antiviral mecha-
nisms. Although tremendous progress has been made toward
understanding the mechanisms underlyingVpu’s functions, many
questions remain regarding how this protein contributes to viral
pathogenesis. Vpu’s contribution to viral immune evasion relies
on its ability to alter the trafﬁcking of its targets by subvert-
ing cellular machineries involved this process. However, despite
some similarities in the mechanisms involved, major differences
have been reported regarding the site of action of Vpu as well
as the fate of its targets in cells. Further characterization of
the mechanisms controlling Vpu expression and distribution
in cells as well as the interplay with its targets and the host
cell machineries might contribute to explain these pleiotropic
effects. In keeping with this line of thought, another fascinat-
ing aspect worthy of further investigation is the role of Vpu with
regards to BST2, in cell-to-cell transmission of HIV through viro-
logical synapses. So far, conﬂicting results have been obtained
regarding the impact of both proteins on this process, but
intriguingly, they have underlined a multifaceted role of BST2
in HIV pathogenesis (Schubert et al., 1995; Gummuluru et al.,
2000; Casartelli et al., 2010; Jolly et al., 2010). Adding to this
complexity, BST2 was recently described to act as a host sensor
of assembled viruses. Therefore, a more detailed characteriza-
tion of BST2’s functions in cells as well as its interplay with
Vpu would contribute to better comprehend the role of both
proteins in viral egress and dissemination. Addressing all these
questions might provide important insights into AIDS patho-
genesis and contribute to the future development of therapeutic
strategies.
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